The decision to suspend clinical trials of cholesterol drug dalcetrapib was a major blow to Roche Ireland in Clarecastle. The company had been developing this drug for nearly five years and invested an estimated $1 billion in trying to bring it to market. Much preparation had taken place at the plant in Clarecastle to lay … Continue reading Decision expected next week at Roche Ireland